Lonza Group Ltd
O6Z
Company Profile
Business description
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
Contact
Muenchensteinerstrasse 38
Basel4002
CHET: +41 613168111
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2026
Employees
16,866
Stocks News & Analysis
stocks
Sales shine but broader macro outlook darkens for this ASX share
US stores are struggling, but our investment thesis hinges on the Australian rollout.
stocks
Chart of the Week: US equity market trading at an attractive discount
The latest from our Chief US Market Strategist.
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
Proposed price regulation impacts our fair value.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,160.40 | 35.30 | 0.39% |
| CAC 40 | 8,263.87 | 355.13 | 4.49% |
| DAX 40 | 24,080.63 | 1,159.04 | 5.06% |
| Dow JONES (US) | 47,909.92 | 1,325.46 | 2.85% |
| FTSE 100 | 10,608.88 | 260.09 | 2.51% |
| HKSE | 25,832.05 | 60.97 | -0.24% |
| NASDAQ | 22,634.99 | 617.14 | 2.80% |
| Nikkei 225 | 55,997.18 | 311.24 | -0.55% |
| NZX 50 Index | 13,287.67 | 33.73 | 0.25% |
| S&P 500 | 6,782.81 | 165.96 | 2.51% |
| S&P/ASX 200 | 8,959.40 | 44.00 | 0.49% |
| SSE Composite Index | 3,975.19 | 19.81 | -0.50% |